|
U.S. Patent Disclosures
(BioWorld Today Via Acquire Media NewsEdge) , of Melbourne, Australia, received a patent related to its lead product, DiabeCell, covering its use in Type I diabetes and the technique for preparing encapsulated neonatal porcine pancreatic islets.
Oncolytics Biotech Inc., of Calgary, Alberta, was granted U.S. Patent No. 7,344,711, titled "Use of Adenoviruses Mutated in the VA Genes for Cancer Treatment." It covers methods of treating cancer using adenoviruses that are modified to selectively replicate in cancer cells that have activated Ras pathway.
Oncothyreon Inc., of Bellevue, Wash., received U.S. Patent No. 7,335,679, relating to PX-867, a small molecule in preclinical development. The patent covers both composition of matter of PX-867 and pharmaceutical preparations containing the compound.
OPKO Health Inc., of Miami, was issued a patent covering methods related to the use and administration of small interfering RNAs for targeting vascular endothelial growth factor, including the company's siRNA drug candidate, bevasiranib, in Phase III studies in wet age-related macular degeneration.
Pipex Pharmaceuticals Inc., of Ann Arbor, Mich., received a notice of allowance for a patent covering the use of thiomolybdates, such as oral tetrathiomolybdate, for the treatment of Alzheimer's disease. It covers the company's anticopper product candidate, oral TTM.
Rosetta Genomics Ltd., of Rehovot, Israel, was issued a notice of allowance for two patents on human and viral microRNAs. The first patent is related to two clustered human hairpins and their related microRNAs, and the second covers microRNA US5-1, a viral microRNA found in human cytomegalovirus.
Santarus Inc., of San Diego, received a notice of allowance for a patent covering methods for treating acid-caused gastrointestinal disorders by administering a solid pharmaceutical composition comprising nonenteric-coated omeprazole and certain antacids.
Sirtris Pharmaceuticals Inc., of Cambridge, Mass., was issued a patent covering a broad class of compounds that activate the SIRT1 enzyme.
Vermillion Inc., of Fremont, Calif., received U.S. Patent No. 7,341,838, covering the discovery of novel forms of brain natriuretic peptide, which potentially could improve the diagnosis and treatment for cardiovascular disease.
?
?
Copyright ? 2008 Thomson BioWorld, All Rights Reserved.
[ Back To TMCnet.com's Homepage ]
|
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, September 16-18, 2008. Los Angeles, California.
